검색어를 입력하세요.
로그인해야 이용 가능합니다.
|
[감염병특허] |
세균 감염병 등장 특허 원문 텍스트 (미국특허) 세균 감염병 등장 특허 원문 텍스트 (미국특허)
|
데이터 기본 이용료
|
| 데이터등록일 | 데이터 수정일 | 데이터 이용기한 | 판매제공처 |
|---|---|---|---|
| 2023-07-20 | 2023-08-23 | 무기한 | BLT |
| 데이터 제공포맷 | 데이터 제공방식 | 데이터 파일용량 | 데이터 상품구분 |
| csv/zip | 다운로드 | 171.49 MB | dataset |
■ 데이터상품설명 ICD 질병분류코드와 MeSH(의학주제표목)에 정의된 세균감염질환을 기준으로 질병별로 정리된 특허데이터를 가공해 제공합니다. 본 데이터 상품은 원문에 가까운 데이터의 제공이 목적이며, 질병/특허번호/날짜/권리자/명칭/초록 등의 정보가 수록되어있습니다. ■ 간략 통계 수록 감염병: 약 600종 (ICD 코드기준 181종, MeSH 코드기준 397종) 수록 특허수: 약 2.4만건 (2023년 02월 현재기준) 질병당 특허수 :평균 250건 (최소1 최대 6977건) ■ 데이터 내용설명 아래와 같은 데이터를 포함하고 있습니다 1) 질병정보 (질병ID/질병코드/질병명) 2) 특허번호정보 (특허ID/출원번호/등록번호) 3) 특허날짜정보 (출원일자/등록일자) 4) 특허권리자 5) 특허원문 (발명의명칭/초록) ■ 참고: ICD10 질병분류코드 코로나바이러스감염증-19 [U07.1] 콜레라 [A00] 결핵 [A15-A19] 디프테리아 [A36] 패혈증 [A40-41] 크로이츠펠트-야콥병 [A81.0] 바이러스수막염 [A87] 지카 바이러스 질환 [A92.5] 황열 [A95] 뎅기 [A97] 에볼라바이러스병 [A98.4] 헤르페스바이러스[단순헤르페스] 감염 [B00] 대상포진 [B02] 바이러스간염 [B15-B19] 인체면역결핍바이러스병 [B20-B24] 감염성 단핵구증 [B27] 백선증 [B35] 칸디다증 [B37] 샤가스병 [B57] 연충증 [B65-B83] 메티실린 내성 황색포도상구균 [U82.1]
|
컨텐츠ID
|
컨텐츠영어명
|
컨텐츠한국어명
|
컨텐츠대분류명
|
질병분류코드
|
MESH분류코드
|
국가코드
|
특허ID
|
특허출원번호
|
특허공개번호
|
특허등록번호
|
특허출원일자
|
특허출원공개일자
|
특허등록일자
|
특허최초공보발행일자
|
현재특허권리자그룹
|
특허발명의명칭제목
|
특허초록
|
메인CPC특허분류코드
|
전체CPC특허분류코드목록
|
CPC특허분류코드개수
|
메인IPC특허분류코드
|
전체IPC특허분류코드목록
|
IPC특허분류코드개수
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 200984 | Bacterial Infection | 세균성 감염 | MeSH_세균 감염 및 진균증 | C01.252 | US | US00004447418B | 06/364761 | 4447418 | 19820402 | 19840508 | 19840508 | Maddoux; Lilla A. | Animal medicine | <p>Manufacture and use of a therapeutic composition which provides for healing of open wounds on animals such as horses while avoiding the development of proud flesh and while acting as a fly repellent and avoiding and curing bacterial infection.</p> | A61K33/04 | A61K33/04|A61K35/06|A61K35/60 | 3 | A61K35/60 | A61K35/60|A61K33/04|A61K35/06 | 3 | |||
| 200984 | Bacterial Infection | 세균성 감염 | MeSH_세균 감염 및 진균증 | C01.252 | US | US00004559333B | 06/585314 | 4559333 | 19840301 | 19851217 | 19851217 | MSD (Merck & Company) | Hydrazone substituted penems | <p>There is disclosed 2-(hydrazonoalkylthio)penems and their pharmaceutically acceptable salts and esters and their use as antibacterials.</p> | C07D205/09 | C07D205/09|C07D499/88|C07F7/1804 | 3 | C07D499/00 | C07D499/00|A61K31/425|C07D205/09|C07D499/88|C07F7/18 | 5 | |||
| 200984 | Bacterial Infection | 세균성 감염 | MeSH_세균 감염 및 진균증 | C01.252 | US | US00005095158B | 07/698415 | 5095158 | 19910510 | 19920310 | 19920310 | Arkema | Solvent extraction of VDC from I-141b | <p>Partial or total separation of a mixture of vinylidene chloride and 1, 1-dichloro-1-fluoroethane by liquid-liquid extraction with solvents having a Hansen solubility parameter of about 30.8-32.0, such as ethanolamine.</p> | C07C17/38 | C07C17/38 | 1 | C07C17/38 | C07C17/38|C07C21/08 | 2 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US00004242270B | 05/910895 | 4242270 | 4242270 | 19780530 | 19801230 | 19801230 | 19801230 | Institut Merieux | Process for separating lipids from endotoxins | <p>Bacterial endotoxins are hydrolyzed to yield lipid fractions which exhibit biological activity equal to, and in some instances greater than, the biological activity of the parent endotoxin.</p> | A61K35/74 | A61K35/74|A61K39/099 | 2 | C11B1/10 | C11B1/10|C09F5/10|A61K35/74|C12N1/20|A61K39/095|A61K39/10 | 6 | |
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US00008377994B2 | 12/299997 | 20090306224 | 8377994 | 20060510 | 20091210 | 20130219 | 20091210 | Evonik Degussa | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions | The use of Sch?lpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described. | A61K9/1611 | A61K9/1611|A61K9/1694 | 2 | A61K47/00 | A61K47/00|A61K31/19|A61K47/02|A61K9/20 | 4 | |
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US00008710082B2 | 13/366278 | 20130345261 | 8710082 | 20120204 | 20131226 | 20140429 | 20131226 | Michigan State University | Benzimidazole inhibition of biofilm formation | The various embodiments relate to a compound comprising: | C07D401/12 | C07D401/12|C07D235/28 | 2 | A61K31/44 | A61K31/44|A61K31/415|C07D401/12|C07D235/28 | 4 | |
| 201134 | Vibrio Infection | 비브리오 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.959 | US | US00006383498B1 | 08/404122 | 6383498 | 19950314 | 20020507 | 20020507 | GlaxoSmithKline (GSK) | Compositions for vaccines | <p>Neuraminidase and galactose oxidase together are a vaccine adjuvant. </p> | A61K39/39 | A61K39/39|A61K2039/55516 | 2 | A61K39/002 | A61K39/002|A61K39/39|A61K38/43|A61K39/12|A61K39/02|A61K38/54 | 6 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US20090075965A1 | 12/205607 | 20090075965 | 20080905 | 20090319 | 20090319 | Protia | DEUTERIUM-ENRICHED AMOXICILIN | The present application describes deuterium-enriched amoxicilin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | C07D499/44 | C07D499/44|A61P31/12|A61P31/04 | 3 | A61K31/43 | A61K31/43|A61P31/04|C07D499/42|A61P31/12 | 4 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US20090149530A1 | 12/192646 | 20090149530 | 20080815 | 20090611 | 20090611 | Herbalscience Group | Antiinfective Flavonol Compounds and Methods of Use Thereof | In one aspect of the invention, the antiinfective agents are flavonol compounds of the represented by formula I: | A61K36/00 | A61K36/00|Y02A50/30|A61P25/28|C07D311/30|A61K31/35|A61P31/12|A61P31/04|A61P31/00 | 8 | A61K31/352 | A61K31/352|A61P25/28|C12Q1/04|C07D311/30|A61P31/12 | 5 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US20090298792A1 | 12/296022 | 20090298792 | 20070330 | 20091203 | 20091203 | Marinomed Biotechnologie | Anti-Inflammatory Polymer | The present invention provides the use of cellulose sulfate or chitosan for the manufacture of an anti-inflammatory pharmaceutical or cosmetic composition for the treatment of inflammation. | A61K31/737 | A61K31/737|A61P29/00|A61P11/02|Y02A50/30|A61K31/722|A61P37/02|A61P31/16 | 7 | A61K31/722 | A61K31/722|A61P37/02|A61K31/717 | 3 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US20110229914A1 | 12/909385 | 20110229914 | 20101021 | 20110922 | 20110922 | University of Rochester | Use of Antibody Secreting Cell Elispot To Assess Antibody Responses Following Antigen Exposure | Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies. | G01N33/56972 | G01N33/56972|G01N33/56911|Y02A50/30|G01N33/56983 | 4 | G01N33/53 | G01N33/53 | 1 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US20140348853A1 | 14/455325 | 20140348853 | 20140808 | 20141127 | 20141127 | University of Texas | METHODS OF TREATING RICKETTSIA USING EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) INHIBITORS | Embodiments of the invention are directed to compounds that inhibit an activity of EPAC proteins and methods of using the same. | A61K31/42 | A61K31/42|Y02A50/30|A61K45/06 | 3 | A61K31/42 | A61K31/42|A61K45/06 | 2 | |||
| 201011 | Gram-Negative Bacterial Infection | 그람 음성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.400 | US | US20160106689A1 | 14/860970 | 20160106689 | 20150922 | 20160421 | 20160421 | Novabiotics | USE | The present invention relates to compositions comprising cysteamine or a derivative thereof for use in treating infections caused by yeasts or moulds. | A61K31/145 | A61K31/145|Y02A50/30|A61K45/06 | 3 | A61K31/145 | A61K31/145|A61K45/06 | 2 | |||
| 201014 | Anaplasmosis | 아나플라스마증 | MeSH_세균 감염 및 진균증 | C01.252.400.054.050 | US | US20100278752A1 | 12/671703 | 20100278752 | 20080725 | 20101104 | 20101104 | HHS (United States Department of Health and Human Services) | Methods for Detection and Prevention of Tick Infestation and Pathogen Transmission | The invention generally features methods for the prevention and detection of a tick infestation. The present invention also features methods for decreasing the ability of a tick to feed on a subject. | A61K39/018 | A61K39/018|Y02A50/30 | 2 | A61B5/00 | A61B5/00|A61K39/00 | 2 | |||
| 201024 | Bordetella Infection | 보르데텔라 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.143 | US | US20050002948A1 | 10/841267 | 20050002948 | 20040507 | 20050106 | 20050106 | Aventis Pasteur | Method of enhanced immunogenicity to meningococcal vaccination | The present invention is a method of enhanced immunogenicity against <i>Neisseria meningitidis </i>serogroups A, C, W-135, and Y. | A61K39/095 | A61K39/095|A61K2039/6037|A61P31/04|A61K2039/55505|A61K39/08|A61K2039/545|A61K39/05|A61P43/00|A61K39/02|A61K2039/70|A61P37/04 | 11 | A61K39/00 | A61K39/00|A61K39/38|A61K39/385 | 3 | |||
| 201024 | Bordetella Infection | 보르데텔라 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.143 | US | US20170080075A1 | 15/140879 | 20170080075 | 20160428 | 20170323 | 20170323 | GSK (GLaxoSmithKline) Biologicals | VACCINE | Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein. | A61K39/095 | A61K39/095|C07K14/195|Y02A50/30|A61P31/04|A61K39/00|A61P31/00|C07K16/1217|A61P29/00|C07K14/22 | 9 | A61K39/095 | A61K39/095|C07K16/12 | 2 | |||
| 201025 | Whooping Cough | 백일해 | MeSH_세균 감염 및 진균증 | C01.252.400.143.740 | US | US00004857318B | 06/715805 | 4857318 | 19850325 | 19890815 | 19890815 | Syntex | Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis | <p>A vaccine derived from Bordetalla bronchiseptica effective against Bordetella pertussis infection is disclosed herein.</p> | C07K14/235 | C07K14/235|Y10S424/825|A61K39/00 | 3 | A61K39/00 | A61K39/00|C12P21/00|C07K14/235 | 3 | |||
| 201025 | Whooping Cough | 백일해 | MeSH_세균 감염 및 진균증 | C01.252.400.143.740 | US | US00008524218B2 | 12/276941 | 20090123444 | 8524218 | 20081124 | 20090514 | 20130903 | 20090514 | David S Terman | Compositions and methods for treatment of neoplastic disease | The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localize in tumors and induce a tumoricidal response. | A61K38/164 | A61K38/164|C12N15/86|A61P35/00|A61K48/00|A61K39/085|C12N15/8636|A61K48/005|A61K45/06|A61K39/0011|A61P37/04 | 10 | A01N63/02 | A01N63/02|A61K39/00|A61K48/00|A61K39/085|A61K35/12 | 5 | |
| 201039 | Chlamydia Infection | 클라미디아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.210.210 | US | US00007323492B2 | 10/752378 | 20040266740 | 7323492 | 20040105 | 20041230 | 20080129 | 20041230 | Paratek Pharmaceuticals | 7-pyrollyl 9-aminoacyl tetracycline compounds and methods of use thereof | A compound of formula (I): | C07D207/333 | C07D207/333|C07D207/34 | 2 | A61K31/40 | A61K31/40|C07D207/46|C07D207/34|C07D207/333|C07D207/32 | 5 | |
| 201025 | Whooping Cough | 백일해 | MeSH_세균 감염 및 진균증 | C01.252.400.143.740 | US | US20140100217A1 | 14/049233 | 20140100217 | 20131009 | 20140410 | 20140410 | Forschungsverbund Berlin|Universitaet zu Koeln (University of Cologne) | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE | The present invention provides a compound comprising a general formula 1: | C07D487/04 | C07D487/04 | 1 | C07D487/04 | C07D487/04 | 1 | |||
| 201025 | Whooping Cough | 백일해 | MeSH_세균 감염 및 진균증 | C01.252.400.143.740 | US | US20150224078A1 | 14/617221 | 20150224078 | 20150209 | 20150813 | 20150813 | Patara Pharma | Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers | Methods for the treatment of lung diseases with mast cell stabilizers are provided. | A61K31/352 | A61K31/352|A61K9/0075|A61K47/02|A61K9/0073|A61K9/12|A61P37/08|A61K9/08|A61P11/06|A61K9/0078|A61P11/00 | 10 | A61K31/352 | A61K31/352|A61K9/00 | 2 | |||
| 201064 | Plague | 페스트 | MeSH_세균 감염 및 진균증 | C01.252.400.310.980.745 | US | US00008911712B2 | 13/877385 | 20130189201 | 8911712 | 20111003 | 20130725 | 20141216 | 20130725 | Church & Dwight | Multi-purposed dentifrice | The present invention is directed towards anhydrous, single-part multi-purposed dentifrice and methods for removing plague, whitening and remineralizing teeth. | A61K8/24 | A61K8/24|A61K8/20|A61K8/19|A61Q11/00|A61K8/22|A61K8/86|A61K2800/31 | 7 | A61K8/24 | A61K8/24|A61Q11/00|A61K8/19|A61K8/22|A61K8/86|A61K8/20 | 6 | |
| 201026 | Borrelia Infection | 보렐리아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.155 | US | US20040142399A1 | 10/675447 | 20040142399 | 20030930 | 20040722 | 20040722 | Gilmore, Robert D|Johnson Barbara Jb | Recombinant FlaA as a diagnostic reagent | <p>The present invention provides for compositions and methods for serological immunoassay for the detection of Lyme disease using recombinant P37/FlaA protein antigen and methods for producing such protein antigen. </p> | C07K14/20 | C07K14/20|C07K2319/00 | 2 | C07K14/20 | C07K14/20|G01N33/569|G01N33/554|C07H21/04 | 4 | |||
| 201026 | Borrelia Infection | 보렐리아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.155 | US | US20080242646A1 | 12/079098 | 20080242646 | 20080325 | 20081002 | 20081002 | Zalicus | Split dose corticosteroid therapy | The invention features methods, compositions, and kits for split dose corticosteroid therapy for the treatment musculoskeletal disorders, periodontal disease, and immunoinflammatory disorders. | A61K31/56 | A61K31/56|Y02A50/30|A61K31/573 | 3 | A61K31/573 | A61K31/573 | 1 | |||
| 201026 | Borrelia Infection | 보렐리아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.155 | US | US20090075967A1 | 12/196762 | 20090075967 | 20080822 | 20090319 | 20090319 | Protia | DEUTERIUM-ENRICHED CEFTRIAXONE | The present application describes deuterium-enriched ceftriaxone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | C07D501/14 | C07D501/14|A61P31/04|A61P31/00 | 3 | C07D501/14 | C07D501/14|A61P31/04|A61K31/546|A61P31/00 | 4 | |||
| 201027 | Lyme Disease | 라임병 | MeSH_세균 감염 및 진균증 | C01.252.400.155.569 | US | US00011326215B2 | 16/686460 | 20200157610 | 11326215 | 20191118 | 20200521 | 20220510 | 20200521 | Rutgers, The State University of New Jersey (Rutgers University, RU) | Multiplex diagnostic assays for Lyme disease and other tick-borne diseases | The present invention provides novel methods of diagnosing and determining treatment strategies for Lyme disease and other tick-borne illnesses. | C12Q1/689 | C12Q1/689|C12Q1/6883|C12Q2600/16|C12Q2600/158 | 4 | C12Q1/689 | C12Q1/689|C12Q1/6883 | 2 | |
| 201112 | Anaplasmosis | 아나플라스마증 | MeSH_세균 감염 및 진균증 | C01.252.400.825.050 | US | US20100278752A1 | 12/671703 | 20100278752 | 20080725 | 20101104 | 20101104 | HHS (United States Department of Health and Human Services) | Methods for Detection and Prevention of Tick Infestation and Pathogen Transmission | The invention generally features methods for the prevention and detection of a tick infestation. The present invention also features methods for decreasing the ability of a tick to feed on a subject. | A61K39/018 | A61K39/018|Y02A50/30 | 2 | A61B5/00 | A61B5/00|A61K39/00 | 2 | |||
| 201039 | Chlamydia Infection | 클라미디아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.210.210 | US | US00006011023B | 08/924419 | 6011023 | 19970827 | 20000104 | 20000104 | Alcon Research | Angiostatic steroids | <p>Methods and compositions for preventing and treating neovascularization with steroids is disclosed.</p> | C07J5/00 | C07J5/00|A61K31/58|A61K31/57|A61K31/573|A61K31/569|C07J53/00|A61K31/665|C07J7/00|A61K31/56|A61K31/565 | 10 | C07J7/00 | C07J7/00|C07J5/00|A01N45/00|C07J53/00|A61K31/569|A61K31/573|A61K31/58|A61K31/56|A61K31/565|A61K31/665|A61K31/57 | 11 | |||
| 201039 | Chlamydia Infection | 클라미디아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.210.210 | US | US20060241084A1 | 10/530800 | 20060241084 | 20031010 | 20061026 | 20061026 | Hospital for Sick Children | Inhibition of vascular endothelial growth factor | This invention relates to therapeutic organic compounds and inhibition of secretion of vascular endothelial growth factor (VEGF) and its effects, including angiogenesis. | A61K31/40 | A61K31/40|A61K31/277|A61K31/216|A61K31/675|A61K31/165|A61K31/662|A61K31/137|A61K31/537 | 8 | A61K31/537 | A61K31/537|A61K31/675|A61K31/40|A61K31/277 | 4 | |||
| 201039 | Chlamydia Infection | 클라미디아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.210.210 | US | US20070197599A1 | 11/669885 | 20070197599 | 20070131 | 20070823 | 20070823 | Colby Pharmaceutical | HYDROXYLAMINES AND DERIVATIVES AS ANTI-ANGIOGENIC AGENTS | The present disclosure provides compounds that include hydroxylamines and ester derivatives thereof and methods for using the same for the treatment of angiogenesis and related diseases. | A61K31/445 | A61K31/445|A61P35/00|A61P27/02|A61P9/00 | 4 | A61K31/445 | A61K31/445|A61K31/421 | 2 | |||
| 201046 | Psittacosis | 앵무병 | MeSH_세균 감염 및 진균증 | C01.252.400.210.250.600 | US | US00007323492B2 | 10/752378 | 20040266740 | 7323492 | 20040105 | 20041230 | 20080129 | 20041230 | Paratek Pharmaceuticals | 7-pyrollyl 9-aminoacyl tetracycline compounds and methods of use thereof | A compound of formula (I): | C07D207/333 | C07D207/333|C07D207/34 | 2 | A61K31/40 | A61K31/40|C07D207/46|C07D207/34|C07D207/333|C07D207/32 | 5 | |
| 201057 | Salmonella Infection | 살모넬라 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.310.821 | US | US00011104663B2 | 16/650670 | 20200247780 | 11104663 | 20180928 | 20200806 | 20210831 | 20200806 | CritiTech | Ciprofloxacin polymorph and its use | The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections. | C07D401/10 | C07D401/10|C07D215/56|A61P31/04|A61K9/14|A61K9/0073 | 5 | C07D401/10 | C07D401/10|A61K9/14|A61K9/00|A61P31/04 | 4 | |
| 201063 | Yersinia Infection | 예르시니아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.310.980 | US | US00010166213B2 | 15/500006 | 20180064680 | 10166213 | 20160422 | 20180308 | 20190101 | 20180308 | Viotika Life Sciences | Derivatives of korormicin useful as antibiotics | An antibiotic compound is of formula (I): | A61K31/341 | A61K31/341|C07F9/65515|A61K2300/00|C07F9/655|A61K31/16|A61K31/365|C07D307/66|C07D309/30|A61P31/04|Y02A50/30 | 10 | A61K31/341 | A61K31/341|C07D307/66|C07F9/655|A61K31/365|C07D309/30|A61K31/16 | 6 | |
| 201063 | Yersinia Infection | 예르시니아 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.310.980 | US | US20050123556A1 | 10/492072 | 20050123556 | 20021007 | 20050609 | 20050609 | Merial | Vaccine against infectious disease | The present invention relates to the use of a protein termed 64p in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites. | A61K39/0003 | A61K39/0003|A61K2039/55566|A61P31/12|Y02A50/30|A61P31/04|A61K2039/58|A61P31/00|A61K2039/55577|A61P25/00 | 9 | A61K39/002 | A61K39/002 | 1 | |||
| 201064 | Plague | 페스트 | MeSH_세균 감염 및 진균증 | C01.252.400.310.980.745 | US | US00006103243B | 08/458814 | 6103243 | 19950602 | 20000815 | 20000815 | Biotechnology | Oral vaccines | <p>The present invention relates to the specific stimulation of serum and secretory antibodies through mucosal presentation of antigens. </p> | A61K47/646 | A61K47/646|A61K39/00|A61K2039/542|A61K2039/6068|C07K2319/40|C07K2319/55|C07K2319/75|A61P37/04 | 8 | A61P37/04 | A61P37/04|A61K47/48|A61K39/00 | 3 | |||
| 201064 | Plague | 페스트 | MeSH_세균 감염 및 진균증 | C01.252.400.310.980.745 | US | US00008293478B2 | 13/258700 | 20120015397 | 8293478 | 20100415 | 20120119 | 20121023 | 20120119 | Kao | Method of using autoinducer-2 as a periodontal disease marker | A marker for determining the onset of periodontal disease and a marker for determining the progression stage of periodontal disease, each containing autoinducer-2. | C12Q1/025 | C12Q1/025|G01N2800/18|A61K31/341|C07H23/00|G01N33/5091|G01N2500/10|C12Q1/18|Y02A50/30|Y02A90/10 | 9 | C12Q1/18 | C12Q1/18|C07C49/17|C07D307/58|C07H23/00|C12Q1/02|C12Q1/68 | 6 | |
| 201064 | Plague | 페스트 | MeSH_세균 감염 및 진균증 | C01.252.400.310.980.745 | US | US20070037776A1 | 11/500612 | 20070037776 | 20060808 | 20070215 | 20070215 | Chu Chia L|Hrkach Jeff|Richardson Tom | Polysaccharides for delivery of active agents | Formulation and methods for modulating the delivery of an agent using polysaccharides. | A61K31/715 | A61K31/715|A61K38/00|A61K9/0073|A61K9/0048|A61K47/36|A61K9/007 | 6 | A61K31/715 | A61K31/715 | 1 | |||
| 201076 | Moraxellaceae Infection | 모락셀라과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.560 | US | US20220259274A1 | 17/717313 | 20220259274 | 20220411 | 20220818 | 20220818 | University of Texas System | METHODS AND COMPOSITIONS RELATED TO RECOMBINANT NEIL2 | Certain embodiments are directed to NEIL2 compositions and method of using NEIL2 composition to treat subjects in need of such treatment. | C07K14/47 | C07K14/47|C12N15/85|C12N9/22|A61P31/04|C12N2015/8518|A61P11/00|C07K2319/01 | 7 | C07K14/47 | C07K14/47|A61P11/00|C12N15/85|A61P31/04 | 4 | |||
| 201078 | Mycoplasmatales Infection | 마이코플라스마탈레스 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.610 | US | US00010174103B2 | 14/913612 | 20160202257 | 10174103 | 20140822 | 20160714 | 20190108 | 20160714 | Tauns | Mycoplasma pneumoniae immunological detection method and kit | [Problem] | C07K16/1253 | C07K16/1253|G01N33/56933|G01N33/54388|G01N2800/26|G01N2333/30 | 5 | C07K16/12 | C07K16/12|G01N33/558|G01N33/569 | 3 | |
| 201083 | Neisseriaceae Infection | 나이세리아과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.625 | US | US00004455142B | 06/338328 | 4455142 | 19820111 | 19840619 | 19840619 | Alza | Method of coadministering an antigen and an immunopotentiator | <p>A method is disclosed for potentiating the immune response of an animal. The method consists in administering an antigen and an immunopotentiator in effective low dose, at a controlled rate, and continuously to produce the desired immune response.</p> | A61K9/0004 | A61K9/0004|A61K39/39 | 2 | A61M13/00 | A61M13/00|A61K9/00|A61K39/39 | 3 | |||
| 201083 | Neisseriaceae Infection | 나이세리아과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.625 | US | US00010414805B2 | 15/905479 | 20190077837 | 10414805 | 20180226 | 20190314 | 20190917 | 20190314 | The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) | Gonorrheal MtrE peptides and vaccines | The invention is directed to MtrE peptides and their use in gonorrhea vaccines. | C07K14/22 | C07K14/22|C07K16/1217|A61K2039/543|A61K2039/55505|C07K2317/34|A61K39/095|A61P31/04|A61K38/00|C07K16/1214 | 9 | C07K14/22 | C07K14/22|A61K39/095|C07K16/12|A61K38/00|A61K39/00 | 5 | |
| 201084 | Gonorrhea | 임질 | MeSH_세균 감염 및 진균증 | C01.252.400.625.391 | US | US00006531120B2 | 10/000462 | 20020098224 | 6531120 | 20011130 | 20020725 | 20030311 | 20020725 | Maxim Pharmaceuticals | Ophthalmic histamine compositions and uses thereof | <p>An ophthalmic composition for use in reducing ocular irritation comprising histamine, at a concentration of between about 0.01 and 1.0% by weight, in a pharmaceutically acceptable carrier, adapted for ophthalmic administration.</p> | A61K9/0048 | A61K9/0048|A61P27/02|A61K31/417|A61K31/4045 | 4 | A61K31/74 | A61K31/74|A61P27/02|A61K31/417|A61K9/00|A61K31/4045 | 5 | |
| 201089 | Pasteurellaceae Infection | 파스튜렐라과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.700 | US | US00010166213B2 | 15/500006 | 20180064680 | 10166213 | 20160422 | 20180308 | 20190101 | 20180308 | Viotika Life Sciences | Derivatives of korormicin useful as antibiotics | An antibiotic compound is of formula (I): | A61K31/341 | A61K31/341|C07F9/65515|A61K2300/00|C07F9/655|A61K31/16|A61K31/365|C07D307/66|C07D309/30|A61P31/04|Y02A50/30 | 10 | A61K31/341 | A61K31/341|C07D307/66|C07F9/655|A61K31/365|C07D309/30|A61K31/16 | 6 | |
| 201089 | Pasteurellaceae Infection | 파스튜렐라과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.700 | US | US00011104663B2 | 16/650670 | 20200247780 | 11104663 | 20180928 | 20200806 | 20210831 | 20200806 | CritiTech | Ciprofloxacin polymorph and its use | The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections. | C07D401/10 | C07D401/10|C07D215/56|A61P31/04|A61K9/14|A61K9/0073 | 5 | C07D401/10 | C07D401/10|A61K9/14|A61K9/00|A61P31/04 | 4 | |
| 201089 | Pasteurellaceae Infection | 파스튜렐라과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.700 | US | US20070054834A1 | 11/400795 | 20070054834 | 20060410 | 20070308 | 20070308 | Nanobio | Quaternary ammonium halides for treatment of infectious conditions | Compositions comprising quaternary ammonium halides and methods of using the compositions comprising quaternary ammonium halides to treat and/or prevent infectious conditions in humans are provided. | A61K31/14 | A61K31/14|A61P15/02|A61P31/20|A61P31/10|A61P15/00|A61P31/18|A61P31/06|A61P31/16|A61P31/04|Y02A50/30|A61P31/14|A61P31/00|A61P31/22|A61P31/12 | 14 | C11D3/00 | C11D3/00 | 1 | |||
| 201092 | Haemophilus Infection | 헤모필루스 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.700.433 | US | US20160038438A1 | 14/782096 | 20160038438 | 20140502 | 20160211 | 20160211 | Helperby Therapeutics | COMBINATION OF NORDIHYDROGUAIARETIC ACID AND AN AMINOGLYCOSIDE | The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections. | A61K31/05 | A61K31/05|Y02A50/30|A61P43/00|A61P31/06|A61P31/04|A61K31/7036 | 6 | A61K31/05 | A61K31/05|A61K31/7036 | 2 | |||
| 201089 | Pasteurellaceae Infection | 파스튜렐라과 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.700 | US | US20200248239A1 | 16/856036 | 20200248239 | 20200423 | 20200806 | 20200806 | Life Technologies | NOVEL COMPOSITIONS, METHODS AND KITS FOR MICROORGANISM DETECTION | Methods, compositions and kits for detecting microorganisms and/or profiling microbiota such as for example through use of nucleic acid amplification and detection. | C12Q1/689 | C12Q1/689|C12Q1/6888|C12Q2600/16|C12Q2600/158|C12Q1/6895 | 5 | C12Q1/689 | C12Q1/689|C12Q1/6888|C12Q1/6895 | 3 | |||
| 201135 | Cholera | 콜레라 | MeSH_세균 감염 및 진균증 | C01.252.400.959.347 | US | US00008710082B2 | 13/366278 | 20130345261 | 8710082 | 20120204 | 20131226 | 20140429 | 20131226 | Michigan State University | Benzimidazole inhibition of biofilm formation | The various embodiments relate to a compound comprising: | C07D401/12 | C07D401/12|C07D235/28 | 2 | A61K31/44 | A61K31/44|A61K31/415|C07D401/12|C07D235/28 | 4 | |
| 201111 | Tick-Borne Disease | 진드기 매개 질병 | MeSH_세균 감염 및 진균증 | C01.252.400.825 | US | US00009694026B2 | 14/778850 | 20160045525 | 9694026 | 20140321 | 20160218 | 20170704 | 20160218 | C7 Sugar | Use of sedoheptulose for prevention or treatment of inflammation | The invention discloses sedoheptulose for use in the prevention or treatment of inflammation. | A61K31/7004 | A61K31/7004|A61P1/02|A61P1/16|A61P27/02|A61P3/04|A61P3/10|A61P25/24|A61P35/00|A61P9/10|A61P25/28|A61P29/00|A61P31/12|A61P37/06|A61P17/00|A61P37/08|A61P11/00|A61P19/10|A61P11/06|A61P17/06|A01N1/0226|A61P19/02|A61P25/00|A61P43/00|A61P1/04|A61P25/16|Y02A50/30|A61K45/06|A61P3/06 | 28 | A61K31/7004 | A61K31/7004|A61K45/06|A01N1/02 | 3 | |
| 201111 | Tick-Borne Disease | 진드기 매개 질병 | MeSH_세균 감염 및 진균증 | C01.252.400.825 | US | US00010718767B2 | 15/916717 | 20190277847 | 10718767 | 20180309 | 20190912 | 20200721 | 20190912 | Id-Fish Technology | Species specific antigen sequences for tick-borne relapsing fever (TBRF) and methods of use | Compositions and methods for the detection and identification of Tick-Borne Relapsing Fever <i>Borrelia </i>sp. antibodies. | C07K14/20 | C07K14/20|G01N33/56911|G01N2333/20|G01N33/581|G01N33/6857|G01N33/582|G01N33/60|G01N2469/20|Y02A50/30 | 9 | G01N33/569 | G01N33/569|G01N33/58|G01N33/68|G01N33/60 | 4 | |
| 201111 | Tick-Borne Disease | 진드기 매개 질병 | MeSH_세균 감염 및 진균증 | C01.252.400.825 | US | US20130078238A1 | 13/635119 | 20130078238 | 20110429 | 20130328 | 20130328 | Hadasit Medical Research Services and Development | Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy | A method or composition comprising an anti-CD3 immune molecule for treatment of hepatitis in a subject. | A61P1/16 | A61P1/16|A61K39/3955|A61P31/14|A61K2039/541|A61K2039/505|C07K16/2809|A61P31/20|Y02A50/30 | 8 | A61K39/395 | A61K39/395 | 1 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00006488934B1 | 09/730930 | 20020192224 | 6488934 | 20001206 | 20021219 | 20021203 | 20021219 | GSK (GLaxoSmithKline) Biologicals | Hepatitis B vaccine | <p>A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.</p> | A61K39/292 | A61K39/292|C12N2730/10134|Y02A50/30|A61K2039/55572|A61K39/12|A61K39/39|A61K2039/55505 | 7 | A61K39/295 | A61K39/295|A61K39/29|A61K39/39 | 3 | |
| 201113 | Ehrlichiosis | 에를리히증 | MeSH_세균 감염 및 진균증 | C01.252.400.825.200 | US | US00006403093B1 | 08/828199 | 6403093 | 19970321 | 20020611 | 20020611 | Mayo Foundation for Medical Education and Research | Methods to detect granulocytic ehrlichiosis | <p>An isolated nucleic acid molecule associated with human granulocytic ehrlichiosis is provided. Also provided are methods to detect the presence of the nucleic acid molecule, and antibodies specific for the polypeptide encoded by the nucleic acid molecule, in a sample derived from a mammal.</p> | C07K14/29 | C07K14/29|A61K39/00|C07K2319/00|A61P39/00|Y10S530/827|Y02A50/30 | 6 | A61P39/00 | A61P39/00|A61K39/00|C12N15/31|C07K14/29 | 4 | |||
| 201113 | Ehrlichiosis | 에를리히증 | MeSH_세균 감염 및 진균증 | C01.252.400.825.200 | US | US20130122041A1 | 13/731958 | 20130122041 | 20121231 | 20130516 | 20130516 | Yissum Research Development of The Hebrew University of Jerusalem | ATTENUATED EHRLICHIOSIS VACCINE | The present invention relates to an attenuated strain of <i>Ehrlichia canis </i>and a vaccine comprising said attenuated strain for protection of mammals against ehrlichiosis. The invention further relates to methods of preventing ehrlichiosis and of attenuating the pathogenicity <i>Ehrlichia canis. </i> | A61K39/0233 | A61K39/0233|A61P37/04|A61P31/04|A61K2039/552|A61K2039/522|C12N1/36 | 6 | A61K39/02 | A61K39/02|C12N1/36 | 2 | |||
| 201122 | Treponemal Infection | 트레포네마 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.840 | US | US00011130937B2 | 16/422155 | 20200032201 | 11130937 | 20190524 | 20200130 | 20210928 | 20200130 | University of Texas System | Compositions and methods for long-term in vitro culture of the syphilis spirochete | Presented herein are compositions and methods for the long-term in vitro culturing of <i>Treponema </i>species such as <i>T. pallidum</i>. Culture media and systems for <i>Treponema </i>culture are also provided. | C12N5/0625 | C12N5/0625|C12N1/20|C12Q1/18|C12N5/0018|G01N2500/10|C12N2502/09|G01N33/5008|C12N5/06|C12N1/18|C12N2502/50|G01N33/571 | 11 | C12N1/18 | C12N1/18|C12N1/20|G01N33/50|C12N5/00|C12N5/07 | 5 | |
| 201124 | Syphilis | 매독 | MeSH_세균 감염 및 진균증 | C01.252.400.840.744 | US | US20150133558A1 | 14/514932 | 20150133558 | 20141015 | 20150514 | 20150514 | Glenn A. Goldstein | USE OF N-ACETYLCYSTEINE AMIDE FOR DECREASING INTRACRANIAL PRESSURE | This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury. | A61K31/16 | A61K31/16|A61P3/00|A61K31/198|Y02A50/30 | 4 | A61K31/16 | A61K31/16 | 1 | |||
| 201115 | Lyme Disease | 라임병 | MeSH_세균 감염 및 진균증 | C01.252.400.825.480 | US | US20120283219A1 | 13/257325 | 20120283219 | 20100325 | 20121108 | 20121108 | Biorelix | DIAMINOPTERIDINE DERIVATIVES | The present invention relates novel diaminopteridine derivatives, their compositions and method of treatment comprising the same for use as anti-infectives. | C07D475/08 | C07D475/08|A61P31/00|A61P13/02|A61P43/00|A61P1/12|A61P31/10|A61P31/04 | 7 | A61K31/519 | A61K31/519|A61K31/675|A61P13/02|A61P31/00|C07F9/6512|A61P1/12|C07D403/12|C07F9/6561|C07D475/08|A61P31/04|A61P31/10 | 11 | |||
| 201124 | Syphilis | 매독 | MeSH_세균 감염 및 진균증 | C01.252.400.840.744 | US | US20130089854A1 | 13/704397 | 20130089854 | 20101210 | 20130411 | 20130411 | Xian Weitong Bioscience | KIT FOR DOT IMMUNOGOLD DIRECTED FILTRATION ASSAY AND USE THEREOF | A kit for dot immunogold directed filtration assay including a dot immunogold directed filtration card, a detection probe labeled by nano colloidal gold or latex beads, a negative standard, a positive standard, and a cleaning solution. | G01N33/5436 | G01N33/5436|G01N33/538|C12Q1/6804|B82Y15/00|Y02A50/30 | 5 | G01N33/543 | G01N33/543 | 1 | |||
| 201122 | Treponemal Infection | 트레포네마 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.840 | US | US00010048258B2 | 15/086340 | 20160216256 | 10048258 | 20160331 | 20160728 | 20180814 | 20160728 | Abbott Point of Care | Oscillating immunoassay method and device | The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field. | G01N33/54333 | G01N33/54333 | 1 | G01N33/543 | G01N33/543 | 1 | |
| 201122 | Treponemal Infection | 트레포네마 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.840 | US | US20120316482A1 | 13/445697 | 20120316482 | 20120412 | 20121213 | 20121213 | Neurosurj Research & Development | ORTHOTIC BONE STIMULATOR | The invention relates to an orthotic bone stimulator and the methods of use pertaining thereto. | A61F5/01 | A61F5/01|A61N1/326 | 2 | A61N1/00 | A61N1/00|A61F5/00 | 2 | |||
| 201122 | Treponemal Infection | 트레포네마 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.840 | US | US20150133558A1 | 14/514932 | 20150133558 | 20141015 | 20150514 | 20150514 | Glenn A. Goldstein | USE OF N-ACETYLCYSTEINE AMIDE FOR DECREASING INTRACRANIAL PRESSURE | This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury. | A61K31/16 | A61K31/16|A61P3/00|A61K31/198|Y02A50/30 | 4 | A61K31/16 | A61K31/16 | 1 | |||
| 201122 | Treponemal Infection | 트레포네마 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.840 | US | US20160050949A1 | 14/832920 | 20160050949 | 20150821 | 20160225 | 20160225 | Prolacta Bioscience | METHODS OF OBTAINING STERILE MILK AND COMPOSITIONS THEREOF | The disclosure provides a simple and effective methods for sterilization of milk without degradation or loss of biologically active agents in the milk and the products produced by such methods. | A23C9/206 | A23C9/206|A23C9/1422|A23C3/02|A23C2210/252 | 4 | A23C9/20 | A23C9/20|A23C3/02 | 2 | |||
| 201124 | Syphilis | 매독 | MeSH_세균 감염 및 진균증 | C01.252.400.840.744 | US | US20160038438A1 | 14/782096 | 20160038438 | 20140502 | 20160211 | 20160211 | Helperby Therapeutics | COMBINATION OF NORDIHYDROGUAIARETIC ACID AND AN AMINOGLYCOSIDE | The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections. | A61K31/05 | A61K31/05|Y02A50/30|A61P43/00|A61P31/06|A61P31/04|A61K31/7036 | 6 | A61K31/05 | A61K31/05|A61K31/7036 | 2 | |||
| 201124 | Syphilis | 매독 | MeSH_세균 감염 및 진균증 | C01.252.400.840.744 | US | US20170128485A1 | 15/206040 | 20170128485 | 20160708 | 20170511 | 20170511 | Bovicor Pharmatech | NITRIC OXIDE TREATMENT OF MAMMARY TISSUE | Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the mammary condition may be mastitis. | A61K33/00 | A61K33/00|A61K9/0014|A61M5/3129|A61D7/00|A61K38/095|A61K9/08|A61K9/0041 | 7 | A61K33/00 | A61K33/00|A61K9/00|A61D7/00|A61K9/08 | 4 | |||
| 201126 | Neurosyphilis | 신경 매독 | MeSH_세균 감염 및 진균증 | C01.252.400.840.744.456 | US | US20170360726A1 | 15/533354 | 20170360726 | 20151204 | 20171221 | 20171221 | Aquinnah Pharmaceuticals | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described. | A61K31/18 | A61K31/18|A61K31/4025|C07D295/108|C07D213/71|A61P25/28|A61K31/44 | 6 | A61K31/18 | A61K31/18|A61K31/4025|A61K31/44|C07D213/71 | 4 | |||
| 201127 | Tabes Dorsalis | 척수 매독 | MeSH_세균 감염 및 진균증 | C01.252.400.840.744.456.778 | US | US20220054609A1 | 17/447607 | 20220054609 | 20210914 | 20220224 | 20220224 | Baylor Scott & White Research Institute (BSWRI) | DENDRITIC CELL ASGPR TARGETING IMMUNOTHERAPEUTICS FOR MULTIPLE SCLEROSIS | Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided. | A61K39/0008 | A61K39/0008|A61P25/00|C07K14/46|C07K2319/33|A61P37/02|A61K2039/577|A61P25/28|A61K2039/505|C07K16/28 | 9 | A61K39/00 | A61K39/00|C07K16/28|C07K14/46 | 3 | |||
| 201133 | Tularemia | 야토병 | MeSH_세균 감염 및 진균증 | C01.252.400.939 | US | US00007057721B2 | 10/608470 | 20050185178 | 7057721 | 20030627 | 20050825 | 20060606 | 20050825 | ChemImage | Wide field method for detecting pathogenic microorganisms | Pathogenic microorganisms are detected in a wide field of view and classified by Raman light scattered light from these organisms together with digital pattern recognition of their spectral patterns. | G01J3/44 | G01J3/44|G01J3/10|G01N21/35|G01J3/02|G01J3/0272|G01N21/6486|G01N21/65|G01N21/6458|G01N2021/656|G01N2201/0221|G01N2021/6417|G01N2021/6423|G01N21/3577 | 13 | G01J3/44 | G01J3/44|G01N21/65|G01J3/02|G01N21/35|G01J3/10|G01N21/64 | 6 | |
| 201133 | Tularemia | 야토병 | MeSH_세균 감염 및 진균증 | C01.252.400.939 | US | US20110286881A1 | 12/801029 | 20110286881 | 20100518 | 20111124 | 20111124 | Vollara Concepts | Methods for controlling and reducing pathogens, allergens odor-causing agents | Disclosed are methods for reducing and/or preventing infection and controlling and/or reducing the level of one or more pathogens, allergens and/or odor-causing agents. | A61L9/015 | A61L9/015|A61L2/208|A61L2/202 | 3 | A61L9/015 | A61L9/015|A61L2/18 | 2 | |||
| 201134 | Vibrio Infection | 비브리오 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.959 | US | US00009926261B2 | 15/066911 | 20160271082 | 9926261 | 20160310 | 20160922 | 20180327 | 20160922 | Rutgers, The State University of New Jersey (Rutgers University, RU) | Bacterial efflux pump inhibitors | Disclosed herein are compounds of formula I: | C07C233/78 | C07C233/78|A61K45/06 | 2 | C07C233/00 | C07C233/00|A61K45/06|A61K31/165|C07C233/78 | 4 | |
| 201134 | Vibrio Infection | 비브리오 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.959 | US | US00009950993B2 | 15/068113 | 20160271081 | 9950993 | 20160311 | 20160922 | 20180424 | 20160922 | Rutgers, The State University of New Jersey (Rutgers University, RU) | Bacterial efflux pump inhibitors | Disclosed herein are compounds of formula I: | C07C233/40 | C07C233/40|A61K45/06|C07C235/34 | 3 | C07C233/00 | C07C233/00|A61K45/06|A61K31/165|C07C233/40|C07C235/34 | 5 | |
| 201134 | Vibrio Infection | 비브리오 감염 | MeSH_세균 감염 및 진균증 | C01.252.400.959 | US | US00011203618B2 | 16/893667 | 20200317737 | 11203618 | 20200605 | 20201008 | 20211221 | 20201008 | University of Arizona | Campylobacter immunogenic compositions and uses thereof | The present disclosure provides immunogenic compositions against <i>Campylobacter </i>and methods for using the immunogenic composition to generate an immune response against <i>Campylobacter </i>and/or reduce intestinal colonization by <i>Campylobacter. </i> | C07K14/205 | C07K14/205|C12N15/74|A61K2039/522|A61K2039/523|A61K2039/53|A61K39/105|A61P31/04 | 7 | C07H21/04 | C07H21/04|C07K14/205|A61K39/02|C12N15/74|A61K39/00 | 5 | |
| 201135 | Cholera | 콜레라 | MeSH_세균 감염 및 진균증 | C01.252.400.959.347 | US | US20050186197A1 | 11/059226 | 20050186197 | 20050216 | 20050825 | 20050825 | Baylor College of Medicine (BCM) | Peptide inhibitors of beta lactamases | Peptide inhibitors of β-lactamases have been identified by the synthesis of peptide arrays using synthesis SPOT technology. These peptide inhibitors of β-lactamase have activity against a broad spectrum of β-lactamases and are useful in a variety of applications. | C07K7/06 | C07K7/06 | 1 | A61K38/54 | A61K38/54|C12N9/99 | 2 | |||
| 201135 | Cholera | 콜레라 | MeSH_세균 감염 및 진균증 | C01.252.400.959.347 | US | US20160015735A1 | 14/771168 | 20160015735 | 20140210 | 20160121 | 20160121 | Areteon | ANTI-MICROBIAL COMPOSITION | A topical anti-microbial composition and use thereof comprising a quaternized chitosan derivative having a polymerizable organic moiety and an amphoteric surfactant. | A61K31/722 | A61K31/722|A61K45/06|A61K31/785|Y02A50/30|A61K31/765|A61P31/04|A61K31/661|A61P29/00|A61K31/22 | 9 | A61K31/722 | A61K31/722|A61K31/661|A61K45/06 | 3 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00004223014B | 05/903430 | 4223014 | 19780508 | 19800916 | 19800916 | Government of the United States of America | Spray immunization of fish | <p>A method for immunizing fish against disease by spraying with vaccine or bacterin.</p> | A61K39/107 | A61K39/107|A61K9/12|Y10S424/827|A61K2039/552 | 4 | A61K39/02 | A61K39/02|A61K39/12|A61K9/12 | 3 | |||
| 201178 | Anthrax | 탄저병 | MeSH_세균 감염 및 진균증 | C01.252.410.090.072 | US | US20100047831A1 | 12/301038 | 20100047831 | 20070517 | 20100225 | 20100225 | University of Nevada, Reno | DIAGNOSIS OF ANTHRAX INFECTION BY DETECTION OF CAPSULAR ANTIGEN IN URINE | The present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum, urine, or other biological samples. | G01N33/56911 | G01N33/56911 | 1 | G01N33/53 | G01N33/53 | 1 | |||
| 201137 | Actinomycetales Infection | 방선균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040 | US | US00010174050B2 | 14/653675 | 20150344498 | 10174050 | 20131220 | 20151203 | 20190108 | 20151203 | Universite de Lille (ULille, UDL, univ-lille)? | Spiroisoxazoline compounds having an activity potentiating the activity of an antibiotic | The present invention concerns a spiroisoxazoline compound of general formula (I): | C07D498/10 | C07D498/10|A61P31/08|A61P43/00|A61K31/435|A61K45/06|A61P31/04|A61P31/06 | 7 | A61K45/06 | A61K45/06|A61K31/435|C07D498/10 | 3 | |
| 201144 | Mycobacterium Infection | 마이코박테리움 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040.552 | US | US00004223040B | 05/527359 | 4223040 | 19741126 | 19800916 | 19800916 | Carroll; John M. | Lauric acid for the prevention and treatment of mycobacterial diseases | <p>A method for the prevention and treatment of mycobacteriosis in mammalian tissue which comprises administering an effective dose of lauric acid.</p> | A61K31/20 | A61K31/20 | 1 | A61K31/20 | A61K31/20 | 1 | |||
| 201145 | Leprosy | 나병 | MeSH_세균 감염 및 진균증 | C01.252.410.040.552.386 | US | US20080040082A1 | 11/788079 | 20080040082 | 20070419 | 20080214 | 20080214 | P&G (Procter & Gamble) | Modeling systems for consumer goods | The present invention relates to modeling systems for designing consumer products and selected components for use in consumer products, consumer products and components selected by such models and the use of same. | G06Q10/04 | G06Q10/04|G16C20/70|G16C20/50|G06Q10/067 | 4 | G06G7/48 | G06G7/48 | 1 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00006911454B1 | 08/293745 | 6911454 | 19940822 | 20050628 | 20050628 | Cancer Biologics | Method for potentiating primary drugs in treating multidrug resistant disease | The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells. | A61K31/70 | A61K31/70|A61K31/47|A61K31/4725|A61K31/4741|A61K31/475|A61K38/04|Y02A50/30|A61K31/44 | 8 | A61K31/47 | A61K31/47|A61K31/4725|A61K31/475|A61K31/4741|A61K31/44|A61K38/04 | 6 | |||
| 201177 | Bacillaceae Infection | 바실루스과 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.090 | US | US00010874679B2 | 16/840239 | 20200230160 | 10874679 | 20200403 | 20200723 | 20201229 | 20200723 | Bill & Melinda Gates Foundation | Boron-containing small molecules | Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed. | A61K31/69 | A61K31/69|C07F5/027|C07F5/025|A61P31/04|A61K45/06 | 5 | A61K31/69 | A61K31/69|A61P31/04|C07F5/02|A61K45/06 | 4 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00007575877B2 | 11/572222 | 20080064051 | 7575877 | 20050720 | 20080313 | 20090818 | 20080313 | Centre for Dna Fingerprinting and Diagnostics | Method of diagnosing tuberculosis | The present invention relates to a method of diagnosing tuberculosis in a subject, said method comprising steps of: detecting anti-<i>Mycobacterium tuberculosis </i>(M.tb.) isocitrate dehydrogenase (ICDs) antibody in the subject, and diagnosing tuberculosis in the subject. | G01N33/5695 | G01N33/5695|G01N2333/904|G01N2469/20 | 3 | G01N33/00 | G01N33/00|A61K39/04|G01N33/53|G01N33/566 | 4 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00007674465B1 | 11/767815 | 7674465 | 20070625 | 20100309 | 20100309 | Drexel University | Regulation of gene expression by the Bacillus anthracis ARP | The invention provides a novel gene and protein regulating the expression of <i>Bacillus anthracis </i>Anthrolysin O toxin, pharmaceutical compositions and antibodies which may be utilized for human or veterinary applications or for agricultural applications, and methods of treatment using same. | C07K14/32 | C07K14/32|C07K2319/60 | 2 | A61K39/00 | A61K39/00|A61K39/02|A61K39/04 | 3 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00008524750B2 | 13/264169 | 20120095064 | 8524750 | 20100413 | 20120419 | 20130903 | 20120419 | GlaxoSmithKline (GSK) | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | A compound of Formula (I) | C07D417/14 | C07D417/14|A61P11/00|A61P31/06 | 3 | A61K31/433 | A61K31/433|A61K31/427|A61K31/4155|C07D285/135|C07D231/16|C07D417/14|A61P31/06 | 7 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00008785479B2 | 13/888084 | 20130296375 | 8785479 | 20130506 | 20131107 | 20140722 | 20131107 | Dow Agrosciences | Macrocyclic picolinamides as fungicides | The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. | A01N43/24 | A01N43/24|A01N47/18|C07D321/00|A01N43/40|A01N2300/00|C07D405/12 | 6 | C07D321/00 | C07D321/00|C07D405/12|A01N43/24|A01N43/40|A01N47/18 | 5 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00008841282B2 | 13/967732 | 20130338119 | 8841282 | 20130815 | 20131219 | 20140923 | 20131219 | Vertex Pharmaceuticals | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | The present invention relates to pyrrolidinone benzenesulfonamides of the following formula: | C07D417/14 | C07D417/14|A61P19/02|A61P25/08|A61P25/22|A61P9/12|A61P25/00|A61P9/06|A61P25/06|A61P1/04|A61P9/10|A61P25/04|A61P25/28|A61P25/24|A61P29/00|A61P25/18 | 15 | C07D417/14 | C07D417/14 | 1 | |
| 201144 | Mycobacterium Infection | 마이코박테리움 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040.552 | US | US00009334265B2 | 14/639241 | 20150307485 | 9334265 | 20150305 | 20151029 | 20160510 | 20151029 | GlaxoSmithKline (GSK) | 3-amino-pyrazole derivatives useful against tuberculosis | A compound of Formula (I) or a pharmaceutically acceptable salt thereof: | C07D417/14 | C07D417/14|A61P31/06|C07D471/04 | 3 | A61K31/44 | A61K31/44|C07D471/04|C07D417/14|C07D285/12 | 4 | |
| 201137 | Actinomycetales Infection | 방선균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040 | US | US00009475846B2 | 13/661409 | 20130142822 | 9475846 | 20121026 | 20130606 | 20161025 | 20130606 | GSK (GLaxoSmithKline) Biologicals | Conjugated Vi saccharides | Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM<sub>197 </sub>(a non-toxic variant of diphtheria toxin) and tetanus toxoid, as carrier proteins. | C07K14/195 | C07K14/195|A61K47/6415|A61K39/0275|A61P43/00|A61P37/04|A61K47/646 | 6 | A61K47/48 | A61K47/48|A61K39/112|C07K14/195 | 3 | |
| 201145 | Leprosy | 나병 | MeSH_세균 감염 및 진균증 | C01.252.410.040.552.386 | US | US00005484952B | 08/238293 | 5484952 | 19940505 | 19960116 | 19960116 | Hercules | Process for the manufacture of alkyl ketene dimer | <p>A process for making an alkyl ketene dimer by the dehydrohalogenation reaction of a C.sub.8 -C.sub.32 aliphatic fatty acid chloride with a tertiary amine in an inert solvent and the product of the process; the solvent comprising at an oxygenated hydrocarbon.</p> | C07D315/00 | C07D315/00|C07C49/88|C07C45/89|C07D305/12 | 4 | C07D305/12 | C07D305/12|C07C49/88|C07C45/89|C07D315/00 | 4 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00009579354B2 | 14/373810 | 20150238551 | 9579354 | 20130123 | 20150827 | 20170228 | 20150827 | Santalis Healthcare|Santalis Pharmaceuticals | Sandalwood oil and its uses related to clostridium infections | Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat, prevent or reduce the recurrence of <i>Clostridium </i>infections. | A61K36/185 | A61K36/185|A61P1/04|A61P31/04|A61P43/00|Y02A50/30|A01N65/08|A61K45/06|A61P1/00 | 8 | A61K36/185 | A61K36/185|A01N65/08|A61K45/06 | 3 | |
| 201137 | Actinomycetales Infection | 방선균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040 | US | US20050124645A1 | 10/926749 | 20050124645 | 20040826 | 20050609 | 20050609 | The Children's Hospital of Philadelphia | Methods and compositions for increasing CD4lymphocyte immune responsiveness | Compositions and methods are provided for the treatment of infections by microbes associated with a latent infection. | A61K45/06 | A61K45/06|G01N33/505|A61K38/45|A61K38/20|A61K31/522|A61K31/00 | 6 | A61K31/4745 | A61K31/4745 | 1 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00009839641B2 | 15/353325 | 20170128458 | 9839641 | 20161116 | 20170511 | 20171212 | 20170511 | Entasis Therapeutics | Compounds and methods for treating bacterial infections | Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed. | A61K31/5383 | A61K31/5383|A61P31/04|Y02A50/30|C07D498/22|A61P43/00 | 5 | C07D498/22 | C07D498/22|A61K31/5383 | 2 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00010004791B2 | 15/122316 | 20170065689 | 10004791 | 20150223 | 20170309 | 20180626 | 20170309 | Affiris Cvd | Peptide vaccines against PCSK9 | The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo. | A61K39/0005 | A61K39/0005|A61P9/00|C12N9/6454|C07K2317/34|A61P35/00|A61K38/00|C07K2319/55|A61P37/04|A61K2039/55516|A61P3/06|C07K16/40|A61K2039/627|A61P9/10|C12Y304/21061|C07K2317/76|A61P35/04|A61K2039/55505|A61P43/00|A61K2039/57 | 19 | C07K16/40 | C07K16/40|C12N9/64|A61K38/00|A61K47/48|A61K39/00 | 5 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00010144767B2 | 15/680429 | 20180051061 | 10144767 | 20170818 | 20180222 | 20181204 | 20180222 | University of Nebraska (UNL, NU) | Anti-microbial peptides and coatings | Antimicrobial peptides and methods of use are provided. | C07K14/4723 | C07K14/4723|C07K7/06|C07K7/08|A61K38/00|A61K45/06|A61K38/17|C12N15/09 | 7 | C07K14/47 | C07K14/47|A61K38/17|C07K7/06|C07K7/08|A61K45/06|A61K38/00|C12N15/09 | 7 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00010190176B2 | 14/649205 | 20150299778 | 10190176 | 20131204 | 20151022 | 20190129 | 20151022 | Boston Medical Center | Primers, probes, and methods for mycobacterium tuberculosis specific diagnosis | This invention pertains to probes, primers and associated methods suitable for the analysis and diagnosis of <i>Myco</i>-<i>bacterium tuberculosis</i>, among other things. | C12Q1/689 | C12Q1/689|C12Q2600/158|C12Q2600/156|C12Q1/6883|C07K14/35 | 5 | C07K14/35 | C07K14/35|C12Q1/689|C12Q1/6883 | 3 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00010493113B2 | 16/190735 | 20190216862 | 10493113 | 20181114 | 20190718 | 20191203 | 20190718 | Evelo Biosciences | Compositions and methods for treating disease using a Blautia strain | Provided herein are methods and compositions related to <i>Blautia </i>Strain A useful as therapeutic agents. | A61K35/742 | A61K35/742|A61K35/74|A61P35/00|A61P37/00|C12N1/20|C12N1/205|C12R2001/01|Y02A50/30 | 8 | A01N63/00 | A01N63/00|A61K35/742|C12R1/01|A61P35/00|A61P37/00 | 5 | |
| 201144 | Mycobacterium Infection | 마이코박테리움 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040.552 | US | US00005658749B | 08/393564 | 5658749 | 19950223 | 19970819 | 19970819 | Integrated Research Technology | Method for processing mycobacteria | <p>A method for the preparation of Mycobacteria from any liquid, semi- solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.</p> | C12Q1/689 | C12Q1/689|C12Q1/6806|G01N33/5695|Y10S435/863|Y10S435/864|Y10S435/865|Y10S435/866|Y10S435/975 | 8 | C12Q1/02 | C12Q1/02|C12Q1/18|C12N1/00|G01N33/569|C12Q1/68 | 5 | |||
| 201144 | Mycobacterium Infection | 마이코박테리움 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040.552 | US | US00006406880B1 | 09/429614 | 6406880 | 19991029 | 20020618 | 20020618 | Integrated Research Technology | Betaines as adjuvants to susceptibility testing and antimicrobial therapy | <p>The present invention is related to methods and compositions for susceptibility testing of bacteria containing mycolic acid structures using betaine-like detergents, and inducing the susceptibility of such bacteria using the same.</p> | C12Q1/18 | C12Q1/18 | 1 | C12N1/06 | C12N1/06|C07G11/00|A01N33/02|C12N1/20|C12Q1/18 | 5 | |||
| 201137 | Actinomycetales Infection | 방선균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410.040 | US | US00005599545B | 08/441785 | 5599545 | 19950516 | 19970204 | 19970204 | Stanford Rook | Mycobacterium as adjuvant for antigens | <p>Immunoregulatry material from a mycobacterium other an M. tuberculosis, especially killed cells of M. vaccae, is an advantageous adjuvant for administration with antigens (including allergens).</p> | A61K39/39 | A61K39/39|A61K2039/55594|A61P31/04 | 3 | A61K39/04 | A61K39/04|A61K39/39|A61P31/04 | 3 | |||
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US00010900072B2 | 14/411224 | 20160201122 | 10900072 | 20130626 | 20160714 | 20210126 | 20160714 | Rutgers, The State University of New Jersey (Rutgers University, RU) | Rapid assays for T-cell activation by RNA measurements using flow cytometry | The present invention relates to a method for rapidly detecting copies of at least one RNA molecule expressed in individual cells and uses thereof. | C12Q1/6841 | C12Q1/6841 | 1 | C12Q1/6841 | C12Q1/6841 | 1 | |
| 201136 | Gram-Positive Bacterial Infection | 그람 양성 세균 감염 | MeSH_세균 감염 및 진균증 | C01.252.410 | US | US000PP034416P2 | 17/300766 | PP034416 | 20211027 | 20220712 | 20220712 | Laymon Robert | Apple tree named ‘Starlord’ | ‘Starlord’ is a new apple tree selected for its resistance to apple Anthracnose, and for its large, flavorful fruit. | A01H6/7418 | A01H6/7418 | 1 | A01H5/08 | A01H5/08|A01H6/74 | 2 |
| 판매제공처 홈페이지 | 판매담당자 | 연락처 | 이메일 |
|---|---|---|---|
| www.BLT.kr | 특허법인BLT | 02-514-0104 | khpark@blt.kr |
| 제약 및 취소/환불 규정 안내 |
|---|
| 데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류, 상이한 데이터에 한하여 구매자가 요구하는 경우 환불을 진행할 수 있습니다. |
홈